Could a probiotic help tame type 1 diabetes? new study tests safety
NCT ID NCT03961347
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a daily probiotic capsule containing Lactobacillus johnsonii N6.2 is safe for adults with type 1 diabetes and whether it affects the immune system. 46 participants took either the probiotic or a placebo for 24 weeks. Researchers monitored blood counts, metabolic panels, and any side effects like stomach discomfort. The goal was to see if this probiotic could help restore gut balance and potentially preserve insulin-producing cells.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lactobacillus johnsonii N6.2 probiotic
What this could lead to
If this probiotic is shown to be safe and to improve immune balance, it could point toward a new way to help manage type 1 diabetes by supporting gut health.
What could go wrong
This is a small, early-phase trial focused on safety and immune markers, not on controlling blood sugar or curing diabetes. The probiotic may have no meaningful effect on the disease itself.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES (T1D) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UF Clinical Research Center
Gainesville, Florida, 32610, United States